The estimated Net Worth of August J Moretti is at least $843 mil dollars as of 21 December 2022. Mr Moretti owns over 3,000 units of 4D Molecular Therapeutics stock worth over $103,673 and over the last 8 years he sold FDMT stock worth over $107,000. In addition, he makes $632,762 as Chief Financial Officer at 4D Molecular Therapeutics.
Mr has made over 4 trades of the 4D Molecular Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of FDMT stock worth $28,230 on 21 December 2022.
The largest trade he's ever made was exercising 5,000 units of 4D Molecular Therapeutics stock on 14 November 2016 worth over $63,450. On average, Mr trades about 1,000 units every 166 days since 2016. As of 21 December 2022 he still owns at least 6,595 units of 4D Molecular Therapeutics stock.
You can see the complete history of Mr Moretti stock trades at the bottom of the page.
August J. Moretti is the Chief Financial Officer at 4D Molecular Therapeutics.
As the Chief Financial Officer of 4D Molecular Therapeutics, the total compensation of Mr Moretti at 4D Molecular Therapeutics is $632,762. There are 1 executives at 4D Molecular Therapeutics getting paid more, with Dr. David H. Kirn having the highest compensation of $701,533.
Mr Moretti is 69, he's been the Chief Financial Officer of 4D Molecular Therapeutics since . There are 1 older and 7 younger executives at 4D Molecular Therapeutics. The oldest executive at 4D Molecular Therapeutics Inc. is August J. Moretti Esq., J.D., 70, who is the Chief Financial Officer.
August's mailing address filed with the SEC is C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE, CA, 94608.
Over the last 4 years, insiders at 4D Molecular Therapeutics have traded over $22,158,915 worth of 4D Molecular Therapeutics stock and bought 2,479,347 units worth $51,074,981 . The most active insiders traders include Global Investors Lp Viking ..., John F Milligan, eGlobal Investors Lp Viking .... On average, 4D Molecular Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $1,516,666. The most recent stock trade was executed by Scott Bizily on 19 August 2024, trading 500 units of FDMT stock currently worth $3,245.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
4D Molecular Therapeutics executives and other stock owners filed with the SEC include: